Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Natalie Shaw · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · 2021 · $119,622 — We confirmed increased ACE2 mRNA and protein expression and functional activity (via a fluorometric assay) in SMCHD1 KO human placode cells. We are now conducting molecular and genomic studies, including RNA-seq, Hi-C, and SMCHD1 ChIP-seq, studies to investigate the precise mechanism underlying epig…
Tara F Carr · UNIVERSITY OF ARIZONA · 2021 · $250,356 — The overall goal of this Asthma and Allergic Diseases Cooperative Research Center (AADCRC) proposal is to elucidate the mechanisms by which the innate immune system affords protection against viral-induced exacerbations in asthma. In the renewal of our AADCRC program, we will continue to focus on th…
Jason Davin Gardner · LSU HEALTH SCIENCES CENTER · 2021 · $396,097 — Project Summary Nicotine is the addictive component of tobacco-derived products. Through binding to a family of nicotinic acetylcholine receptors (nAChRs), nicotine influences a diverse range of cellular mechanisms involved in homeostasis and disease. Although cigarette smoking is a major risk fact…
Karen Scanlon · UNIVERSITY OF MARYLAND BALTIMORE · 2021 · $193,125 — PROJECT SUMMARY Pertussis, caused by Bordetella pertussis, is a reemerging disease of major public health concern. Pertussis severity is age-related, with B. pertussis causing severe manifestations that are unique to young infants and not observed at an older age. These infants are at increased risk…
HENRY DANIELL · UNIVERSITY OF PENNSYLVANIA · 2021 · $785,508 — PROJECT SUMMARY/ABSTRACT Current Protein Drugs (PD) are prohibitively expensive ($140 billion in top ten PDs, >75% of global GDP). One third of global population earning <$2 per day can’t afford any PD. Insulin, a five-decade old drug, is still unaffordable, even in developed countries, as illustra…
Cynthia Ann Derdeyn · EMORY UNIVERSITY · 2021 · $234,563 — SUMMARY Clinical sequelae of COVID-19 patients include not only acute respiratory distress syndrome (ARDS), but also often acute kidney injury and heart failure. These pathologies share endothelial activation as a common underlying early response to injury, and endothelial cells express high levels …
CARLOS M FERRARIO · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2021 · $232,500 — Project Summary The burden of high blood pressure, a major public health problem, is aggravated by an aging human population. A plethora of experimental data points to angiotensin II (Ang II), as the major contributing factor in the development of hypertension-related target organ damage. Although …
ROBERT M LAVKER · NORTHWESTERN UNIVERSITY AT CHICAGO · 2021 · $397,703 — PROJECT SUMMARY/ABSTRACT The anterior surface of the eye functions as a barrier to the external environment and protects the delicate underlying structures from injury, in part, through the elaboration of the limbal and corneal epithelia. It is well- accepted that the limbal epithelium is the site o…
DIRK HOMANN · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2021 · $453,320 — ABSTRACT The possibility that infection with SARS-CoV-2 may trigger diabetes emerged as a concern in mid 2020. We have addressed this issue by developing a research roadmap that identified complementary areas of investigation according to several broad topics in the realm of relevant basic biomedica…
BHAGAVATULA MOORTHY · BAYLOR COLLEGE OF MEDICINE · 2021 · $240,720 — Project Summary Severe coronavirus disease (COVID-19) is caused by a novel Beta-coronavirus, now named SARS-CoV-2. COVID-19 is characterized by unresolved systemic hyperinflammation associated with a life-threatening “cytokine storm syndrome”, leading to multi-organ failure dysfunction in some pati…
Shelli Farhadian · YALE UNIVERSITY · 2021 · $417,822 — Project Summary The COVID-19 pandemic has rampantly affected the population of the world and created lasting effects on the economy, health and psyche of the global community. Although it shares similarities with SARS-CoV-1, the full extent of the pathophysiology caused by SARS-CoV-2 is unclear. In …
Sara Cherry · UNIVERSITY OF PENNSYLVANIA · 2021 · $224,752 — Summary The current outbreak of the coronavirus in China (SARS-CoV-2) has spread rapidly. There are experimental drugs which will be tested; however, there are no approved therapeutics or vaccines. Indeed, there are tests underway to determine whether remdesivir, which was developed against filoviru…
Gaya K. Amarasinghe · WASHINGTON UNIVERSITY · 2021 · $667,277 — Project Summary/Abstract This R01 entitled, “Development and characterization of engineered therapeutic antibodies against SARS-CoV- 2”, builds on our project infrastructure, expertise, and experience in characterizing viral-host factor interactions in negative strand RNA viruses. Since originating …
BINA JOE · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · 2021 · $231,750 — 7. Project Summary/Abstract Animal models fare indispensable for understanding the pathology of COVID-19 as well as for developing vaccines. They are also important to discern the etiology of COVID-19 in specific groups at risk, such as individuals with pre-existing hypertension. While there are ham…
Anna R Hemnes · VANDERBILT UNIVERSITY MEDICAL CENTER · 2021 · $1,678,313 — SUMMARY Pulmonary Arterial Hypertension is a lethal disease with devastating impact on thousands of patients and families. Our team has studied this tragic disease for more than 3 decades and the progressive knowledge derived from that work now promises to greatly improve outcomes. Our overall theme…
Aaron Gregory Schmidt · MASSACHUSETTS GENERAL HOSPITAL · 2021 · $239,867 — Project Summary There is urgent need for the development of effective countermeasures against the newly emerged novel coronavirus or “nCoV” (also known as COVID-19). The development of a “universal” coronavirus (CoV) vaccine would not only be effective against COVID-19 but, in theory, would protect …
Michael Edwin Boulton · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2021 · $391,180 — This proposal examines the hypothesis that diabetes results in a pathological change in the communication between the bone marrow (BM) and gut leading to dysfunction in both compartments. Angiotensin converting enzyme 2 (ACE2) converts angiotensin II (ANG II) to angiotensin 1-7(Ang 1-7) which, by vi…
Alexander Minchev Tsankov · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2021 · $839,491 — PROJECT SUMMARY The new coronavirus (SARS-CoV-2) and associated disease (COVID-19) is a global threat to worldwide economies and public health due to its highly contagious nature and rapid spread. To develop optimal strategies for treatment of COVID-19, it is critical to understand the cell types an…
MARK C CHAPPELL · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2021 · $27,020 — ABSTRACT Hypertension is the leading risk factor for cardiovascular disease, is highly prevalent with high lifetime cumulative incidence rates, and is the leading cause of death compared to any other risk factor. Premature birth is an emerging and important risk factor for hypertension and cardiovas…
Tejal A. Desai · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2021 · $828,473 — PROJECT SUMMARY: The COVID-19 pandemic, caused by the new coronavirus SARS-CoV-2, has had a remarkable impact on public health worldwide with the largest number of cases and deaths reported in the United States. Improved understanding of COVID-19 will accelerate the development of effective therapeu…